Adipokines and Systemic Lupus Erythematosus: Relationship with Metabolic Syndrome and Cardiovascular Disease Risk Factors

REFERENCES

1. 1.↵
   1. Bjornadal L,
   2. Yin L,
   3. Granath F,
   4. Klareskog L,
   5. Ekbom A

   . Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol 2004;31:713–9.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Dekker JM,
   2. Girman C,
   3. Rhodes T,
   4. et al

   . Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005;112:666–73.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Chung CP,
   2. Avalos I,
   3. Oeser A,
   4. et al

   . High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007;66:208–14.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Tilg H,
   2. Moshen AR

   . Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature 2006;6:772–83.

   OpenUrl
5. 5.↵
   1. Lago F,
   2. Dieguez C,
   3. Gòmez-Reino J,
   4. Gualillo O

   . The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007;18:313–25.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Otero M,
   2. Lago R,
   3. Gomez R,
   4. et al

   . Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198–201.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Sada KE,
   2. Yamasaki Y,
   3. Maruyama M,
   4. et al

   . Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006;33:1545–52.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Bokarewa M,
   2. Bokarew D,
   3. Hultgren O,
   4. Tarkowski A

   . Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:952–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Hochberg MC

   . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.

   OpenUrlPubMed
10. 10.↵
    1. Griffiths B,
    2. Mosca M,
    3. Gordon C

    . Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:685–708.

    OpenUrlCrossRefPubMed
11. 11.↵
    Progetto CUORE. Epidemiologia e prevenzione delle malattie cerebro e cardiovascolari. [Internet. Accessed October 14, 2008.] Available from: http://www.cuore.iss.it/
12. 12.↵
    1. World Health Organization

    . Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organization; 1999.
13. 13.↵
    1. Balkau B,
    2. Charles MA

    . Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442–3.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Beltowsku J

    . Leptin and atherosclerosis. Atherosclerosis 2006;189:47–60.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Wallace AM,
    2. McMahon AD,
    3. Packard CJ,
    4. et al

    . Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001;104:3052–6.

    OpenUrlAbstract/FREE Full Text